Abstract

The University of Texas M. D. Anderson Cancer Center is proposing a Lymphoma Specialized Program of Research Excellence (SPORE). The primary goal of this Lymphoma SPORE is to improve the cure rate of lymphoma through innovative therapeutic strategies based on effective and focused translation of recent discoveries in lymphoma biology, immunology, and molecular genetics. The M. D. Anderson Lymphoma SPORE is a multidisciplinary collaborative effort between basic and translational scientists, clinical investigators, hematopathologists, and biostatisticians that is organized in 4 research projects and 4 core resources, as well as programs for developmental research and career development program. The research projects listed are designed to target specific areas important in lymphoma: Project 1 - Epigenetic-based therapy of Hodgkin lymphoma (Liu/Younes) Project 2 - Development of 8-chloro-adenosine therapy (Gandhi/McLaughlin) Project 3 - Targeting MDM2/P53 in ALL (Andreeff/O'Brien) Project 4 - Gene expression profiling and pathway targeted therapy in peripheral T-cell lymphoma (Chan/Vose) Core and other resources are the following: Core A - Administrative Core B - Biospecimen Core C - Clinical Research Core D - Biostatistics and Bioinformatics Development Research Program (DRP) and Career Development Program (CDP)

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA136411-03
Application #
8120295
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Program Officer
Nothwehr, Steven F
Project Start
2009-09-01
Project End
2013-08-31
Budget Start
2011-09-01
Budget End
2013-08-31
Support Year
3
Fiscal Year
2011
Total Cost
$475,000
Indirect Cost

  Institution

Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030

  Publications

Zhang, Jun; Medeiros, L Jeffrey; Young, Ken H (2018) Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Front Oncol 8:351
Yao, Z; Deng, L; Xu-Monette, Z Y et al. (2018) Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia 32:353-363
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Dufva, Olli; Kankainen, Matti; Kelkka, Tiina et al. (2018) Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun 9:1567
Xu-Monette, Zijun Y; Zhou, Jianfeng; Young, Ken H (2018) PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131:68-83
Wang, Jinfen; Xu-Monette, Zijun Y; Jabbar, Kausar J et al. (2017) AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol 187:1700-1716
Xia, Y; Xu-Monette, Z Y; Tzankov, A et al. (2017) Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia 31:625-636
Gong, Qiang; Wang, Chao; Zhang, Weiwei et al. (2017) Assessment of T-cell receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq data. Sci Rep 7:11301
Sekihara, Kazumasa; Saitoh, Kaori; Han, Lina et al. (2017) Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget 8:34552-34564
Visco, Carlo; Wang, Jinfen; Tisi, Maria Chiara et al. (2017) Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. Br J Cancer 117:1685-1688

Showing the most recent 10 out of 137 publications